שווי כולל של החברה: purple-biotech.com (PPBT)

Purple Biotech develops treatments to combat resistant forms of malignant neoplasms by suppressing tumor defense systems. The company is implementing automated clinical data analysis systems and robotic molecule screening. Serving as the primary valuation tool, this chart of quotes on GURU.Markets shows an Enterprise Value of -4.39, highlighting the potential of the CM24 antibody, which renders cancer cells vulnerable to the immune system.

Enterprise value reflects the actual costs of business acquisition, summing market capitalization and net debt to eliminate distortions from leveraged capital. An analysis of the total buyout price for Purple Biotech (PPBT) allows for an assessment of the company's financial stability, where a diversified portfolio of anti-tumor molecules mitigates regulatory risks, making the estimated asset value more justified for a long-term investor.